Update on Pharmacotherapy for Irritable Bowel Syndrome

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2019 Apr 27

PMID 31025114

Citations 7

Authors

Akhil Munjal

Bhavtosh Dedania

Brooks Cash

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Irritable bowel syndrome (IBS) is a functional GI disorder that affects a large percentage of the population and presents a significant socio-economic burden on the society. In this article, we reviewed the evidence supporting various pharmacological treatment options for IBS.

Recent Findings: Rifaximin, eluxadoline, and alosetron have demonstrated that they reduce symptom severity improving quality of life in patients with IBS-diarrhea. Ramosetron is a promising agent in development. Peppermint oil has also demonstrated a positive impact on some symptoms of IBS. For IBS with constipation, traditional laxatives have failed to demonstrate significant benefit. However, lubiprostone, linaclotide, and plecanatide have demonstrated improvement of IBS with constipation in large, placebo-controlled trials. Tenapanor, a sodium/hydrogen exchanger 3 inhibitor, appears to be a promising treatment option in the pipeline. There are multiple pharmacologic agents with a variety of mechanisms that have demonstrated efficacy in IBS with diarrhea and constipation. There are no established pharmacologic agents for IBS with a mixed bowel pattern. There is a promising pipeline for additional novel therapies for IBS.

Citing Articles

The Mechanism of Relieving Diarrheal Irritable Bowel Syndrome Using Polyphenols from L. Based on a Network Pharmacology Analysis and 16S rRNA Sequencing.

Yu X, Wang X, Liu X, Li F, Bao Y, Chai Y Foods. 2024; 13(23).

PMID: 39682940 PMC: 11640074. DOI: 10.3390/foods13233868.

Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na/H Exchanger Isoform 3.

Jacobs J, Leadbetter M, Bell N, Koo-McCoy S, Carreras C, He L ACS Med Chem Lett. 2022; 13(7):1043-1051.

PMID: 35859876 PMC: 9290029. DOI: 10.1021/acsmedchemlett.2c00037.

Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Li X, Li B, Zhang J, Chen T, Wu H, Shi X Medicine (Baltimore). 2021; 100(4):e24361.

PMID: 33530231 PMC: 7850711. DOI: 10.1097/MD.0000000000024361.

Shortcomings of Trials Assessing Antidepressants in the Management of Irritable Bowel Syndrome: A Critical Review.

Oh S, Takakura W, Rezaie A J Clin Med. 2020; 9(9).

PMID: 32932856 PMC: 7564007. DOI: 10.3390/jcm9092933.

Efficacy of HA-196 and R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.

Lewis E, Antony J, Crowley D, Piano A, Bhardwaj R, Tompkins T Nutrients. 2020; 12(4).

PMID: 32326347 PMC: 7230591. DOI: 10.3390/nu12041159.

References

Camilleri M, Northcutt A, Kong S, Dukes G, McSorley D, Mangel A . Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000; 355(9209):1035-40. DOI: 10.1016/S0140-6736(00)02033-X. View

Hills J, Aaronson P . The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991; 101(1):55-65. DOI: 10.1016/0016-5085(91)90459-x. View

Drossman D, Chey W, Johanson J, Fass R, Scott C, Panas R . Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2008; 29(3):329-41. DOI: 10.1111/j.1365-2036.2008.03881.x. View

Pimentel M, Lembo A, Chey W, Zakko S, Ringel Y, Yu J . Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364(1):22-32. DOI: 10.1056/NEJMoa1004409. View

Chey W, Drossman D, Johanson J, Scott C, Panas R, Ueno R . Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012; 35(5):587-99. DOI: 10.1111/j.1365-2036.2011.04983.x. View

Wade P, Palmer J, McKenney S, Kenigs V, Chevalier K, Moore B . Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. Br J Pharmacol. 2012; 167(5):1111-25. PMC: 3492991. DOI: 10.1111/j.1476-5381.2012.02068.x. View

Lucak S . Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron. Therap Adv Gastroenterol. 2012; 5(4):215-8. PMC: 3388526. DOI: 10.1177/1756283X12450934. View

Cremonini F, Nicandro J, Atkinson V, Shringarpure R, Chuang E, Lembo A . Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012; 36(5):437-48. PMC: 3464357. DOI: 10.1111/j.1365-2036.2012.05208.x. View

Occhipinti K, Smith J . Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2013; 25(1):46-52. PMC: 3348735. DOI: 10.1055/s-0032-1301759. View

10.

Dove L, Lembo A, Randall C, Fogel R, Andrae D, Davenport J . Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013; 145(2):329-38.e1. DOI: 10.1053/j.gastro.2013.04.006. View

11.

Shailubhai K, Comiskey S, Foss J, Feng R, Barrow L, Comer G . Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013; 58(9):2580-6. DOI: 10.1007/s10620-013-2684-z. View

12.

Khanna R, MacDonald J, Levesque B . Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2013; 48(6):505-12. DOI: 10.1097/MCG.0b013e3182a88357. View

13.

Raschi E, De Ponti F . Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2014; 10(2):293-305. DOI: 10.1517/17425255.2013.876410. View

14.

Layer P, Stanghellini V . Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014; 39(4):371-84. PMC: 4305214. DOI: 10.1111/apt.12604. View

15.

Pimentel M, Chang C, Chua K, Mirocha J, DiBaise J, Rao S . Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014; 59(6):1278-85. DOI: 10.1007/s10620-014-3157-8. View

16.

Wilson D, Evans M, Weaver E, Shaw A, Klein G . Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2014; 6:49-60. PMC: 4020402. DOI: 10.4137/CGast.S13200. View

17.

Love B, Johnson A, Smith L . Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014; 71(13):1081-91. DOI: 10.2146/ajhp130575. View

18.

Canavan C, West J, Card T . Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9):1023-34. DOI: 10.1111/apt.12938. View

19.

Zielinska M, Wasilewski A, Fichna J . Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Investig Drugs. 2015; 24(8):1093-9. DOI: 10.1517/13543784.2015.1054480. View

20.

Cash B, Epstein M, Shah S . A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci. 2015; 61(2):560-71. PMC: 4729798. DOI: 10.1007/s10620-015-3858-7. View